Federated Hermes’s MoonLake Immunotherapeutics MLTX Stock Holding History

Federated Hermes’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,248,573	Closed	-$58.9M	–	2187
2025 Q2	$58.9M	Sell	1,248,573 -20,778	-2%	-$846K	0.11%	230
2025 Q1	$49.6M	Sell	1,269,351 -10,701	-0.8%	-$461K	0.11%	238
2024 Q4	$69.3M	Buy	1,280,052 +149,724	+13%	+$7.65M	0.15%	182
2024 Q3	$57M	Buy	1,130,328 +1,900	+0.2%	+$89K	0.13%	214
2024 Q2	$49.6M	Buy	1,128,428 +28,672	+3%	+$1.21M	0.12%	221
2024 Q1	$55.2M	Buy	1,099,756 +39,230	+4%	+$2.13M	0.13%	210
2023 Q4	$64M	Sell	1,060,526 -23,724	-2%	-$1.22M	0.16%	163
2023 Q3	$61.8M	Sell	1,084,250 -85,249	-7%	-$4.71M	0.16%	159
2023 Q2	$59.6M	Buy	1,169,499 +365,000	+45%	+$9.82M	0.15%	175
2023 Q1	$17.2M	Buy	+804,499	New	+$13.5M	0.04%	433

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Federated Hermes's MLTX Position: Q3 2025 in Review

Federated Hermes sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 1,248,573 shares — an estimated $58.9M sold.

Federated Hermes first reported a position in MLTX in Q1 2023 and held it in 10 quarters. The position peaked at $69.3M in Q4 2024. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

Federated Hermes reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
Federated Hermes sold 1,248,573 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $58.9M.
Federated Hermes first reported a position in MoonLake Immunotherapeutics in Q1 2023 and held it in 10 quarters.
Federated Hermes's MoonLake Immunotherapeutics position peaked at $69.3M in Q4 2024.
134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.